Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Exelixis and Bristol-Myers Squibb partner in cancer therapy
Under the terms of the collaboration agreement between the two companies, which became effective in January 2007, the selection of XL139 by Bristol-Myers Squibb entitles Exelixis to a
Under the terms of the collaboration agreement between the two companies, which became effective in January 2007, the selection of XL139 by Bristol-Myers Squibb entitles Exelixis to a
The international Phase III randomized, double-blind, placebo-controlled study will compare standard of care treatment (SoC) versus SoC plus NeuVax for the prevention of recurrence in early-stage, node-positive breast
Under the terms of the merger agreement, Roche will amend its existing tender offer to acquire all of the outstanding common shares of Ventana to reflect the terms
The addition of HealthTrust expands Masimo’s GPO contracts to include all 10 of the nation’s top GPOs, allowing hospitals and other care providers increased access to Masimo SET
According to the company, IriSys successfully formulated the GeNOsys tablets into a product that could be manufactured in high quantities yet maintain the necessary tablet hardness, appropriate generated
These devices, according to the company, represent entirely new platforms to treat heart failure and sudden cardiac death and are the result of a multi-year research and development
The study, conducted at the Institute of Hematology and Medical Oncology at University of Bologna, Italy, investigated the use of a single dose of Zevalin (Ibritumomab Tiuxetan) as
Under terms of the agreement, Teva will pay a purchase price of $400 million cash, funded from its internal resources. The transaction has been approved by the boards
The open label Phase III study will evaluate the efficacy, safety and tolerability of the TLT therapy in the treatment of patients with mild-to-moderate toenail onychomycosis. The TLT
The placebo-controlled, double-blind, three-dose study measured drug effect and pattern of response using quantitative electroencephalography (EEG) in healthy volunteers, who all received each dose plus placebo. After each